Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions
This map shows the geographic impact of Jane Armitage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Armitage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Armitage more than expected).
This network shows the impact of papers produced by Jane Armitage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Armitage. The network helps show where Jane Armitage may publish in the future.
Co-authorship network of co-authors of Jane Armitage
This figure shows the co-authorship network connecting the top 25 collaborators of Jane Armitage.
A scholar is included among the top collaborators of Jane Armitage based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Jane Armitage. Jane Armitage is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Kitas, George D., Peter Nightingale, Jane Armitage, et al.. (2015). Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis. Arthritis & Rheumatism. 67.4 indexed citations
6.
Li, Xi, Fang Feng, Haibo Zhang, et al.. (2013). [ACEI/ARB use among high risk patients with coronary heart disease in China: a cross-sectional study].. PubMed. 41(1). 18–22.1 indexed citations
7.
Armitage, Jane. (2011). Randomised trials remain essential and are not overrated. The Journal of the Royal College of Physicians of Edinburgh. 41. 129–131.1 indexed citations
8.
Jiang, Lixin, et al.. (2010). [A cross-sectional study on the use of statin among patients with atherosclerotic ischemic stroke in China].. PubMed. 31(8). 925–8.4 indexed citations
9.
Jiang, Lei, et al.. (2010). Survey of statin usage in 4429 diabetic patients with atherosclerostic cardiovascular disease in China. 15. 264–268.2 indexed citations
10.
Parish, Stanley T., Alison Offer, Alexander G. Thompson, et al.. (2010). Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality. Journal of Internal Medicine. 268. 348–358.29 indexed citations
11.
Rahimi, Kazem, Jonathan Emberson, Paul McGale, et al.. (2009). Effect of statins on atrial fibrillation: a collaborative meta-analysis of randomised controlled trials. Oxford University Research Archive (ORA) (University of Oxford).13 indexed citations
12.
Rahimi, Kazem, Paul McGale, William Majoni, et al.. (2009). Effect of statins on ventricular arrhythmic events: a collaborative meta-analysis of randomised controlled trials. European Heart Journal. 30. 591–591.1 indexed citations
13.
Hopewell, Jemma C., et al.. (2009). No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study. Circulation. 120.3 indexed citations
14.
Armitage, Jane & Louise Bowman. (2009). Therapeutic Strategies in Lipid Disorders. 15–28.2 indexed citations
Armitage, Jane & Spencer J. Williams. (1988). INHALER TECHNIQUE IN THE ELDERLY. Age and Ageing. 17(4). 275–278.79 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.